General Information of Drug Transporter (DT)
DT ID	DTD0023 Transporter Info
Gene Name	SLC22A5
Protein Name	Organic cation/carnitine transporter 2
Gene ID	6584
UniProt ID	O76082
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs2631367
Site of GPD	chr5:132369766 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.2670/1337 (Global)
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the increased drug response in patients (compare with genotype CC)		[ 1]
Imatinib	N.A.	Overall Survival	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 1]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 1]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Sunitinib	N.A.	Overall Survival	Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 2]
Imatinib	N.A.	Overall Survival	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 3]
Imatinib	N.A.	Drug Toxicity	Allele C is not associated with likelihood of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 3]
Imatinib	N.A.	Discontinuation	Allele C is not associated with likelihood of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 3]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.		[ 1]
Genetic Polymorphism	rs2631372
Site of GPD	chr5:132367886 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>C
Minor Allele Frequency	C=0.3347/1676 (Global)
Genotypes CG + GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the increased drug response in patients (compare with genotype CC)		[ 1]
Imatinib	N.A.	Overall Survival	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 1]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes CG + GG are associated with increased response to imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC.		[ 1]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Sunitinib	N.A.	Overall Survival	Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 2]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Imatinib	N.A.	Overall Survival	Allele G is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 3]
Imatinib	N.A.	Drug Toxicity	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 3]
Imatinib	N.A.	Discontinuation	Allele G is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele C.		[ 3]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype and gastrointestinal stromal tumours may have a shorter time to progression when treated with imatinib, as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression.		[ 1]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GG genotype and gastrointestinal stromal tumours may have a longer time to progression when treated with imatinib, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence time to progression.		[ 1]
Genetic Polymorphism	rs274558
Site of GPD	chr5:132385482 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.4862/2435 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Imatinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the decreased periorbital edema risk in patients (compare with genotype GG)		[ 4]
Imatinib	N.A.	Drug Toxicity	Genotypes AA + AG is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.		[ 4]
Imatinib	N.A.	Eye Diseases	Genotypes AA + AG is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.		[ 4]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes AA + AG is associated with decreased risk of Drug Toxicity and Eye Disorder when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype GG.		[ 4]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AA genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.		[ 4]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.		[ 4]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for periorbital edema when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.		[ 4]
Genetic Polymorphism	rs2631370
Site of GPD	chr5:132368084 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.5310/1050 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Sunitinib	N.A.	Overall Survival	Allele C is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 2]
Imatinib	N.A.	Overall Survival	Allele C is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 3]
Imatinib	N.A.	Drug Toxicity	Allele C is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 3]
Imatinib	N.A.	Discontinuation	Allele C is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele T.		[ 3]
References
1	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2013 Feb;68(1):1-6.
2	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. Pharmacogenomics J. 2018 Jan;18(1):49-55.
3	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
4	Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2018 May 22;18(3):460-466.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.